Immunome (NASDAQ:IMNM) Issues Quarterly Earnings Results, Misses Expectations By $0.16 EPS

Immunome (NASDAQ:IMNM) issued its quarterly earnings data on Wednesday. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome Stock Performance

Immunome stock traded up $0.21 during midday trading on Wednesday, reaching $8.57. 522,477 shares of the company’s stock were exchanged, compared to its average volume of 810,302. Immunome has a 52 week low of $8.34 and a 52 week high of $26.70. The firm has a market cap of $683.69 million, a price-to-earnings ratio of -1.06 and a beta of 1.93. The stock’s 50-day simple moving average is $9.89 and its 200 day simple moving average is $11.66.

Insider Buying and Selling

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 8.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have issued reports on IMNM. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome currently has a consensus rating of “Buy” and an average price target of $27.17.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.